SCHEMBL6080368

SCHEMBL6080368

O=C(O)c1cc(CCCCCO)c2cccc(O)c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.46
KMT2A Q03164 2/20 0.46
BID P55957 7/20 0.41
MCL1 Q07820 7/20 0.41
BCL2L1 Q07817 6/20 0.41
BAK1 Q16611 6/20 0.41
KAT8 Q9H7Z6 2/20 0.41
SAE1 Q9UBE0 2/20 0.41
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
EP300 Q09472 1/20 0.41
KAT2A Q92830 1/20 0.41
KAT2B Q92831 1/20 0.41
KAT5 Q92993 1/20 0.41
MEN1 O00255 1/20 0.40
MAPT P10636 2/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
ALOX12 P18054 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080167 0.95 KDM4E (0.48) KDM4EKMT2ABIDMCL1BCL2L1
SCHEMBL6080305 0.88 BID (0.56) KDM4EKMT2ABIDMCL1BCL2L1
SCHEMBL6080099 0.85 KDM4E (0.47) KDM4EKMT2ABIDMCL1BCL2L1
Hydrochloric Acid SCHEMBL6080927 0.84 KDM4E (0.46) KDM4EKMT2ABIDMCL1BCL2L1
SCHEMBL6079288 0.81 KDM4E (0.51) KDM4EKMT2ABIDMCL1BCL2L1
SCHEMBL6080554 0.81 CYP4A11 (0.40) KDM4EKMT2AMEN1MAPTLMNA
SCHEMBL6079612 0.81 CYP4A11 (0.40) KDM4EKMT2AMEN1MAPTLMNA
SCHEMBL6605390 0.80 FDPS (0.38) KDM4EKMT2ATSHRIGFBP5MMP2
Hydrochloric Acid SCHEMBL6080849 0.79 FDPS (0.37) KDM4EKMT2ATSHRIGFBP5MMP2
SCHEMBL6599193 0.79 HDAC3 (0.45) MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL KDM4E 1006/4885KMT2A 1384/4885BID 2995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.